Beijing Hotgen Biotech Co., Ltd.

Total Valuation

Beijing Hotgen Biotech Co., Ltd. carries a market capitalization of 12.52B, placing it among publicly traded companies globally. Its enterprise value stands at 11.65B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Beijing Hotgen Biotech Co., Ltd. currently has 92.71M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 26.16, and the price-to-book ratio stands at 4.44.

Enterprise Valuation

Financial Position

Beijing Hotgen Biotech Co., Ltd. maintains a current ratio of 4.50, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.71, indicating elevated leverage, while an interest coverage ratio of -220.07 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Beijing Hotgen Biotech Co., Ltd. has paid -694,793.58 in income taxes, reflecting an effective tax rate of 42.90.

Stock Price Statistics

Beijing Hotgen Biotech Co., Ltd.'s stock has declined approximately -26.16899% over the past 52 weeks. The 50-day moving average sits at 92.94, while the 200-day moving average is 137.54.

Income Statement

Over the trailing twelve months, Beijing Hotgen Biotech Co., Ltd. generated 466.00M in revenue and converted that into -244.93M in net income, yielding earnings per share of -2.93. EBITDA reached -149.46M, while operating income came in at -149.46M.

Balance Sheet

Beijing Hotgen Biotech Co., Ltd. holds 582.62M in cash and equivalents against 50.22M in total debt, resulting in a net debt position of -133.89M. Total book value stands at 2.75B, with working capital of 1.04B providing operational flexibility.

Cash Flow

After subtracting -23.13M in capital expenditures, free cash flow totaled -23.13M - equivalent to -0.27 per share.

Margins

Beijing Hotgen Biotech Co., Ltd. operates with a gross margin of 57.48, reflecting its pricing power and cost economics. The operating margin of -32.07 and net profit margin of -52.56 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -2.16 indicates the proportion of earnings distributed to shareholders.

Stock Splits

Beijing Hotgen Biotech Co., Ltd.'s most recent stock split took place on June 16, 2022 with a 25:37 split ratio.

Scores

Beijing Hotgen Biotech Co., Ltd. posts an Altman Z-Score of 25.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.